LCRF partners with Daiichi Sankyo & AstraZeneca to fund ADC research
The Lung Cancer Research Foundation has reportedly collaborated with Daiichi Sankyo and AstraZeneca in order to fund three research grants emphasizing on the development of ADCs (antibody drug conjugates). This research will help devise better methods for the treatment of patients suffering from lung cancer.
This research will focus on the study of a wide range of TROP2 directed and HER2 directed ADCs which includes biomarkers, mechanism of action, and resistance mechanisms. Early phase trials of ADCs in non-small cell lung cancer are already underway, with satisfactory results being observed.
The three new research grants will further aid in the study of potential applications of the antibody drug conjugates in several types of lung cancers.
The Chairperson of the LCRF Scientific Advisory Board, Katerina Politi, Ph.D., has commented that the specific focus of the research funding is ADCs and their application in lung cancer treatment. She further hailed ADCs as a promising area in lung cancer research.
ADCs target cancer cells specifically, as opposed to traditional chemotherapy, thereby limiting damage to healthy cells. The cytotoxic agent known as payload, also plays an important role in the cure of the disease, by binding to a monoclonal antibody that can identify proteins in cancer cells.
Lung cancer is one of the most common reasons for cancer-related deaths in the U.S. and around the globe. It is rarely detected in its early stages and presents only when a patient shows aggressive symptoms, in its advanced stages. The possibility of reoccurrence after the initial treatment is also in this form of cancer.
For the record, the Lung Cancer Research Foundation is a non-profit organization which is focused on innovative funding and high-reward research focused on the prevention, diagnosis, and treatment of lung cancer as well as improvement in the quality of life of patients. LCRF has funded 409 research grants to date, which is the highest amount of funding provided by a nonprofit organization toward furthering lung cancer research.
